Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30

$9.45−0.09 (-0.94%)

Close on Nov 13, 2026Market cap $843.86MP/E –Yield –

Syndax Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Syndax Pharmaceuticals's EV/EBITDA was 817.8× on Oct 31, 2022.

Period	Period end	Value	Change (pts)
2022	Oct 31, 2022	817.8×	–

Parsed from the XBRL in Syndax Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SNDX.

Revenue growth159.7% · median 2.2%

Operating margin-61.7% · median -63.0%

Net margin-72.3% · median -44.9%

Advertisement
300 × 250

See a number that looks wrong?